Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Patient-reported outcomes in etanercept-treated psoriasis patients

A randomized, double-blind, placebo-controlled phase III trial assessed the effects of etanercept in children aged 4-17 years with psoriasis. The Children's Dermatology Life Quality Index (CDLQI) was used to assess quality of life and the Psoriasis Area and Severity Index (PASI) was used to assess disease severity. Over 2-12 weeks, the mean percentage improvement from baseline in total CDLQI was 27-52% in the etanercept group versus 8-18% in the placebo group (p = 0.0333, p = 0.0046 and p = 0.0001, respectively for weeks 2, 4 and 12). Placebo-treated patients were then treated for 12 weeks with open-label etanercept and achieved a mean improvement of 41% at 24 weeks that was ...